Anti-RUNX1 / AML1 antibody (ab35962)
Key features and details
- Rabbit polyclonal to RUNX1 / AML1
- Suitable for: WB
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-RUNX1 / AML1 antibody
See all RUNX1 / AML1 primary antibodies -
Description
Rabbit polyclonal to RUNX1 / AML1 -
Host species
Rabbit -
Tested applications
Suitable for: WBmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse, Rat, Chicken
-
Immunogen
Synthetic peptide conjugated to KLH derived from within residues 400 to the C-terminus of Human RUNX1/ AML1.
Read Abcam's proprietary immunogen policy (Peptide available as ab38695.)
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.40
Preservative: 0.02% Sodium azide
Constituent: PBS
Batches of this product that have a concentration
Concentration information loading...Purity
Immunogen affinity purifiedClonality
PolyclonalIsotype
IgGResearch areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
Our Abpromise guarantee covers the use of ab35962 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application Abreviews Notes WB Use a concentration of 0.25 µg/ml. Detects a band of approximately 53 kDa (predicted molecular weight: 49 kDa). Target
-
Function
CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter. Inhibits MYST4-dependent transcriptional activation. -
Tissue specificity
Expressed in all tissues examined except brain and heart. Highest levels in thymus, bone marrow and peripheral blood. -
Involvement in disease
Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.
Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.
Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.
Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.
Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.
Defects in RUNX1 are the cause of familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]. FPDMM is an autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia.
Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.
Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16. -
Sequence similarities
Contains 1 Runt domain. -
Domain
A proline/serine/threonine rich region at the C-terminus is necessary for transcriptional activation of target genes. -
Post-translational
modificationsPhosphorylated in its C-terminus upon IL-6 treatment. Phosphorylation enhances interaction with MYST3.
Methylated. -
Cellular localization
Nucleus. - Information by UniProt
-
Database links
- Entrez Gene: 861 Human
- Entrez Gene: 12394 Mouse
- Entrez Gene: 50662 Rat
- Omim: 151385 Human
- SwissProt: Q01196 Human
- SwissProt: Q03347 Mouse
- SwissProt: Q63046 Rat
- Unigene: 149261 Human
see all -
Alternative names
- Acute myeloid leukemia 1 antibody
- Acute myeloid leukemia 1 protein antibody
- alpha subunit core binding factor antibody
see all
Images
-
Western blot - Anti-RUNX1 / AML1 antibody (ab35962)All lanes : Anti-RUNX1 / AML1 antibody (ab35962) at 1 µg/ml
Lane 1 : Jurkat nuclear extract lysate (ab14844)
Lane 2 : MOLT4 (Human acute lymphoblastic leukemia cell line) Whole Cell Lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/10000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 49 kDa
Observed band size: 52,54,55 kDa why is the actual band size different from the predicted?
Additional bands at: 47 kDa, 75 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 10 seconds -
Western blot - Anti-RUNX1 / AML1 antibody (ab35962)RUNX2 recombinant protein full length, with N-terminal HIS tag, expressed in E.Coli.
RUNX3 overexpression and empty vector control lysates created in HEK293T cells. The protein contains a C-terminal DDK tag.
References (7)
ab35962 has been referenced in 7 publications.
- Serrano-Coll H et al. Notch Signaling Pathway Expression in the Skin of Leprosy Patients: Association With Skin and Neural Damage. Front Immunol 11:368 (2020). PubMed: 32265900
- Liang Z et al. Down-regulation of lncRNA-NEF indicates poor prognosis in intrahepatic cholangiocarcinoma. Biosci Rep 39:N/A (2019). PubMed: 31015363
- Shi X et al. Clonal expansion and myeloid leukemia progression modeled by multiplex gene editing of murine hematopoietic progenitor cells. Exp Hematol 64:33-44.e5 (2018). WB . PubMed: 29751067
- Zhao H et al. KSRP specifies monocytic and granulocytic differentiation through regulating miR-129 biogenesis and RUNX1 expression. Nat Commun 8:1428 (2017). PubMed: 29127290
- Zape JP et al. Cell cycle dynamics and complement expression distinguishes mature haematopoietic subsets arising from hemogenic endothelium. Cell Cycle 16:1835-1847 (2017). PubMed: 28820341
- Cheng Y et al. RUNX1 promote invasiveness in pancreatic ductal adenocarcinoma through regulating miR-93. Oncotarget 8:99567-99579 (2017). PubMed: 29245924
- Tsunoda T et al. Immune-related zinc finger gene ZFAT is an essential transcriptional regulator for hematopoietic differentiation in blood islands. Proc Natl Acad Sci U S A 107:14199-204 (2010). IHC-P ; Mouse . PubMed: 20660741
Images
-
Western blot - Anti-RUNX1 / AML1 antibody (ab35962)All lanes : Anti-RUNX1 / AML1 antibody (ab35962) at 1 µg/ml
Lane 1 : Jurkat nuclear extract lysate (ab14844)
Lane 2 : MOLT4 (Human acute lymphoblastic leukemia cell line) Whole Cell Lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/10000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 49 kDa
Observed band size: 52,54,55 kDa why is the actual band size different from the predicted?
Additional bands at: 47 kDa, 75 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 10 seconds
-
Western blot - Anti-RUNX1 / AML1 antibody (ab35962)
RUNX2 recombinant protein full length, with N-terminal HIS tag, expressed in E.Coli.
RUNX3 overexpression and empty vector control lysates created in HEK293T cells. The protein contains a C-terminal DDK tag.
